rethinkPeptides Search
Menu
Study breakdown

Scientists Create Blood Pressure-Friendly Ricotta Cheese Using Bioactive Peptides From Dairy Waste

Basic ResearchPreliminary evidence
The takeaway

Researchers developed a functional ricotta cheese enriched with ACE-inhibitory peptides derived from dairy waste whey through ultrafiltration and bacterial fermentation, delivering about 30 mg of bioactive peptides per 100g serving.

~30 mg bioactive peptides per 100g serving

Ricotta cheese fortified at 5% with fermented whey retentate, containing κ-casein-derived ACE-inhibitory peptide fragments identified by mass spectrometry

What the researchers found

The biotechnological protocol combined membrane ultrafiltration (to concentrate proteins from waste whey) with fermentation by a selected L. helveticus strain. The fermented product had high anti-ACE activity.

Peptides responsible for the activity were identified by mass spectrometry. Their sequences overlapped with known kappa-casein antihypertensive fragments.

Fortified ricotta cheese results:

- 5% fortification: a 100g portion contained approximately 30 mg of bioactive peptides

- Significantly higher anti-ACE activity compared to control and unfermented versions

- Moderate changes in texture (increased hardness and chewiness)

- Decreased milk odor/taste but improved flavor persistence and sapidity

- Microbiological quality was acceptable

Why it matters

Cheese whey is one of the most abundant dairy waste products. Turning it into a source of bioactive peptides creates value from waste while producing a functional food that could help manage blood pressure naturally.

The numbers in context

~30mg bioactive peptides/100g at 5% fortification; kappa-casein fragments; L. helveticus fermentation; ACE inhibition confirmed

How the study worked

Ricotta cheese exhausted whey was ultrafiltered and the protein-rich retentate was fermented with L. helveticus. Bioactive peptides were identified by nano-LC-ESI-MS/MS. The fermented retentate was spray-dried and added to ricotta cheese at 1% and 5%. Products were evaluated for microbiological, chemical, functional, textural, and sensory properties.

Who was studied

Food technology study, no human subjects

What this study cannot tell us

Anti-ACE activity in a food product does not guarantee blood pressure reduction in people. The peptides must survive further digestion and reach the bloodstream. No human clinical trial was performed. The 30 mg per 100g serving may or may not be enough for a clinical effect. Sensory changes (increased hardness, less milk taste) could affect consumer acceptance.

How to read the evidence

This is a food technology development study demonstrating proof of concept for a functional food product. ACE inhibition was confirmed in vitro, but no human clinical data exists to show actual blood pressure-lowering effects from consuming this fortified cheese.

When this study was published

Published in 2021, this study is part of the ongoing trend toward functional food development and dairy waste valorization. The approach builds on decades of research into dairy-derived antihypertensive peptides.

The bigger picture

Dairy-derived bioactive peptides — particularly from casein fermented by Lactobacillus species — are among the best-studied food-derived antihypertensive compounds, with products like Calpis sour milk and Evolus fermented milk already on the market in Japan and Europe. This study extends the approach to ricotta cheese while simultaneously addressing the dairy industry's whey waste problem, demonstrating a circular economy model for functional food production.

Questions still open

  • Would regular consumption of this fortified ricotta cheese produce measurable blood pressure reduction in a clinical trial?
  • How stable are these bioactive peptides during the ricotta cheese's shelf life and through gastrointestinal digestion?
  • Could this whey fermentation approach be scaled commercially, and what would the cost implications be for the final product?

Common questions

Can eating special cheese really lower blood pressure?
Some fermented dairy products containing specific peptides have shown modest blood pressure-lowering effects in clinical trials — products like Calpis sour milk in Japan contain ACE-inhibitory peptides. However, this particular fortified ricotta hasn't been tested in humans yet, and the amount of peptides per serving may or may not be sufficient for a clinical effect. It's best viewed as a healthier food option rather than a replacement for blood pressure medication.
How does turning dairy waste into bioactive peptides work?
The process starts with waste whey from ricotta production, which still contains proteins. These proteins are concentrated using ultrafiltration (a membrane technique) and then fermented with Lactobacillus helveticus bacteria, which naturally break proteins into small peptide fragments. Some of these fragments happen to match sequences known to inhibit ACE. The fermented product is spray-dried into a powder that can be added back to cheese during production.

Read the original research

Antihypertensive Peptides from Ultrafiltration and Fermentation of the Ricotta Cheese Exhausted Whey: Design and Characterization of a Functional Ricotta Cheese.

Foods (Basel, Switzerland), 10(11)

Citation

Pontonio, Erica; Montemurro, Marco; De Gennaro, Gina Valeria; Miceli, Valerio; Rizzello, Carlo Giuseppe. (2021). Antihypertensive Peptides from Ultrafiltration and Fermentation of the Ricotta Cheese Exhausted Whey: Design and Characterization of a Functional Ricotta Cheese.. Foods (Basel, Switzerland), 10(11). https://doi.org/10.3390/foods10112573